全文获取类型
收费全文 | 4407篇 |
免费 | 278篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 134篇 |
妇产科学 | 100篇 |
基础医学 | 414篇 |
口腔科学 | 67篇 |
临床医学 | 250篇 |
内科学 | 1381篇 |
皮肤病学 | 142篇 |
神经病学 | 283篇 |
特种医学 | 78篇 |
外科学 | 654篇 |
综合类 | 76篇 |
现状与发展 | 2篇 |
一般理论 | 3篇 |
预防医学 | 573篇 |
眼科学 | 93篇 |
药学 | 175篇 |
中国医学 | 22篇 |
肿瘤学 | 239篇 |
出版年
2023年 | 64篇 |
2022年 | 69篇 |
2021年 | 173篇 |
2020年 | 160篇 |
2019年 | 395篇 |
2018年 | 297篇 |
2017年 | 180篇 |
2016年 | 145篇 |
2015年 | 145篇 |
2014年 | 194篇 |
2013年 | 245篇 |
2012年 | 108篇 |
2011年 | 143篇 |
2010年 | 114篇 |
2009年 | 102篇 |
2008年 | 124篇 |
2007年 | 107篇 |
2006年 | 88篇 |
2005年 | 74篇 |
2004年 | 64篇 |
2003年 | 43篇 |
2002年 | 38篇 |
2001年 | 47篇 |
2000年 | 28篇 |
1999年 | 36篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 17篇 |
1993年 | 8篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 80篇 |
1984年 | 170篇 |
1983年 | 134篇 |
1982年 | 139篇 |
1981年 | 145篇 |
1980年 | 102篇 |
1979年 | 125篇 |
1978年 | 118篇 |
1977年 | 75篇 |
1976年 | 103篇 |
1975年 | 83篇 |
1974年 | 78篇 |
1973年 | 73篇 |
排序方式: 共有4719条查询结果,搜索用时 203 毫秒
41.
《Journal of clinical lipidology》2020,14(2):161-169
South Asian risk for atherosclerotic cardiovascular disease (ASCVD) has received special emphasis in the 2018 US AHA/ACC/Multisociety Cholesterol Guidelines. The term “South Asian” refers specifically to the countries of India, Pakistan, Nepal, Bhutan, Bangladesh, Sri Lanka, and Maldives and to the worldwide diaspora of families from these countries. With this definition, approximately 25% of the world's population is South Asian, but about 50% of ASCVD occurs in this group. In this JCL Roundtable, we discuss the roles of visceral adiposity, diabetes, and features of the metabolic syndrome; lipoprotein(a); and diet and lifestyle, including the transition of both diet and lifestyle over the past 40 to 50 years. Genetic and/or hidden risk is an area of ongoing research. Individual patient assessment and intervention should recognize the earlier onset of ASCVD and the value of screening for traditional risk factors as well as waist circumference, coronary artery calcium scoring, and lipoprotein(a) assay. Culturally acceptable dietary strategies are available, although not widely implemented or evaluated as yet. In very-high-risk cases of secondary prevention, one should consider combining medications to drive low-density lipoprotein cholesterol much lower than 70 mg/dL. Our discussion concludes by insisting that the signal of alarm must be accompanied by decisive action. 相似文献
42.
43.
《Journal of infection and chemotherapy》2021,27(10):1384-1388
Non-chlamydial non-gonococcal urethritis (NCNGU) is defined as urethritis with neither Neisseria gonorrhoeae nor Chlamydia trachomatis. Possible causative agents of NCNGU include Mycoplasma genitalium, Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis, Trichomonas vaginalis, and so on. Among these microorganisms, the pathogenicity of M. genitalium and T. vaginalis to the male urethra has been confirmed so far.The Asian Association of Urinary Tract Infection and Sexually Transmitted Infection (AAUS) belonging to the Urological Association of Asia (UAA) had developed the guidelines regarding NCNGU and the present guidelines were updated from previous edition. Relevant references were meticulously reviewed again and latest studies were collected. In addition to the levels of evidence, the recommendation grades were defined using the modified GRADE methodology. Herein, we present the new edition of the UAA-AAUS guidelines for M. genitalium and non-chlamydial non-gonococcal urethritis. 相似文献
44.
45.
《Journal de Mycologie Médicale》2021,31(2):101123
Papiliotrema laurentii (formerly Cryptococcus laurentii) and Papiliotrema albidus (formerly Cryptococcus albidus) are yeast-like environmental fungi which are largely considered as non-pathogenic to humans. However, invasive infections caused by P. laurentii have recently been reported in some patients with an impaired immune system. Here, we describe the first case of P. laurentii fungemia in a premature, very low-birth-weight neonate in Kuwait and the Middle East. Repeated bloodstream isolates were obtained and were tentatively identified as P. laurentii by Vitek 2 yeast identification system. The identification of the yeast isolates as P. laurentii was confirmed by PCR-sequencing of ribosomal DNA (rDNA). Antifungal susceptibility testing data showed that the isolates were susceptible to amphotericin B, fluconazole and voriconazole but appeared resistant to caspofungin. The baby was successfully treated with liposomal amphotericin B. 相似文献
46.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
47.
《Journal of Cardiovascular Computed Tomography》2022,16(3):222-229
ObjectivesTo investigate potential differences in plaque progression (PP) between in East Asians and Caucasians as well as to determine clinical predictors of PP in East Asians.BackgroundStudies have demonstrated differences in cardiovascular risk factors as well as plaque burden and progression across different ethnic groups.MethodsThe study comprised 955 East Asians (age 60.4 ?± ?9.3 years, 50.9% males) and 279 Caucasians (age 60.4 ?± ?8.6 years, 74.5% males) who underwent two serial coronary computed tomography angiography (CCTA) studies over a period of at least 24 months. Patients were enrolled and analyzed from the PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging) registry. After propensity-score matching, plaque composition and progression were compared between East Asian and Caucasian patients. Within East Asians, the plaque progression group (defined as plaque volume at follow-up CCTA minus plaque volume at baseline CCTA> 0) was compared to the no PP group to determine clinical predictors for PP in East Asians.ResultsIn the matched cohort, baseline volumes of total plaque as well as all plaque subtypes were comparable. There was a trend towards increased annualized plaque progression among East Asians compared to Caucasians (18.3 ?± ?24.7 ?mm3/year vs 16.6 ?mm3/year, p ?= ?0.054). Among East Asians, 736 (77%) had PP. East Asians with PP had more clinical risk factors and higher plaque burden at baseline (normalized total plaque volume of144.9 ?± ?233.3 ?mm3 vs 36.6 ?± ?84.2 ?mm3 for PP and no PP, respectively, p ?< ?0.001). Multivariate logistic regression analysis showed that baseline normalized plaque volume (OR: 1.10, CI: 1.10–1.30, p ?< ?0.001), age (OR: 1.02, CI: 1.00–1.04, p ?= ?0.023) and body mass index (OR: 2.24, CI: 1.01–1.13, p ?= ?0.024) were all predictors of PP in East Asians. Clinical events, driven mainly by percutaneous coronary intervention, were higher among the PP group with a total of 124 (16.8%) events compared to 22 (10.0%) in the no PP group (p ?= ?0.014).ConclusionEast Asians and Caucasians had comparable plaque composition and progression. Among East Asians, the PP group had a higher baseline plaque burden which was associated with greater PP and increased clinical events. 相似文献
48.
Wen Da Guan Chris Ka Pun Mok Zi Lin Chen Li Qiang Feng Zheng Tu Li Ji Cheng Huang Chang Wen Ke Xilong Deng Yun Ling Shi Guan Wu Xue Feng Niu Ranawaka A Perera Yuan Da Xu Jincun Zhao Lin Qi Zhang Yi Min Li Rong Chang Chen Malik Peiris Ling Chen Nan Shan Zhong 《Emerging infectious diseases》2015,21(12):2278-2280
49.
This is a systematic review of existing data on dietary selenium (Se) intake and status for various population groups in Europe (including the United Kingdom (UK)) and the Middle East. It includes English language systematic reviews, meta-analyses, randomised controlled trials, cohort studies, cross-sectional and case-control studies obtained through PUBMED searches from January, 2002, to November, 2014, for European data and from 1990 to November 2014, for Middle Eastern data. Reports were selected if they included data on Se intake and status. The search identified 19 European/UK studies and 15 investigations in the Middle East that reported Se intake and Se concentration in water and/or food and 48 European/UK studies and 44 investigations in the Middle East reporting Se status. Suboptimal Se status was reported to be widespread throughout Europe, the UK and the Middle East, and these results agreed with previous reports highlighting the problem. Eastern European countries had lower Se intake than Western European countries. Middle Eastern studies provided varying results, possibly due to varying food habits and imports in different regions and within differing socioeconomic groups. In conclusion, Se intake and status is suboptimal in European and Middle Eastern countries, with less consistency in the Middle East. 相似文献
50.
S. N. Wekesa V. B. Muwanika H. R. Siegismund A. K. Sangula A. Namatovu M. T. Dhikusooka K. Tjrnehj S. N. Balinda J. Wadsworth N. J. Knowles G. J. Belsham 《Transboundary and Emerging Diseases》2015,62(3):305-314
Foot‐and‐mouth disease (FMD) is endemic in Kenya where four serotypes (O, A, SAT 1 and SAT 2) of the virus are currently in circulation. Within 2010 and 2011, the National Laboratory recorded an increase in the number of FMD outbreaks caused by serotype O virus. The characteristics of these viruses were determined to ascertain whether these were independent outbreaks or one single strain spreading throughout the country. The sequences of the complete VP1‐coding region were analysed from viruses sampled within different areas of Kenya during 2010 and 2011. The results indicated that the 2010 to 2011 outbreaks in Kenya were caused by four independent strains. By comparison with earlier type O isolates from Eastern Africa, it was apparent that the outbreaks were caused by viruses from three different lineages of topotype EA‐2 and a fourth virus strain belonging to topotype EA‐4. The topotypes EA‐1 and EA‐3 were not detected from these outbreaks. Implications of these results for FMD control in Eastern Africa are discussed. 相似文献